- Home
- INMB
as 02-21-2025 4:00pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 203.5M | IPO Year: | 2019 |
| Target Price: | $21.50 | AVG Volume (30 days): | 462.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $13.52 | Next Earning Date: | 03-27-2025 |
| Revenue: | $42,000 | Revenue Growth: | -81.25% |
| Revenue Growth (this year): | -93.16% | Revenue Growth (next year): | N/A |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%
TipRanks
10 days ago
INmune Bio price target raised to $23 from $22 at Scotiabank
GlobeNewswire
10 days ago
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
MT Newswires
12 days ago
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe
GlobeNewswire
12 days ago
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Insider Monkey
19 days ago
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025
GlobeNewswire
25 days ago
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
TipRanks
a month ago
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.